{"id":"gallium","rwe":[],"_fda":{"id":"04ba7ec2-1ea0-b828-e063-6394a90abb12","route":[""],"set_id":"04ba7eb9-db5d-fa7f-e063-6294a90aff7e","openfda":{"unii":["46F059V66A"],"route":["ORAL"],"spl_id":["04ba7ec2-1ea0-b828-e063-6394a90abb12"],"brand_name":["Gallium Oxydatum"],"spl_set_id":["04ba7eb9-db5d-fa7f-e063-6294a90aff7e"],"package_ndc":["37662-3867-1","37662-3867-2","37662-3867-3","37662-3867-4","37662-3870-1","37662-3870-2","37662-3870-3","37662-3870-4","37662-3865-1","37662-3865-2","37662-3865-3","37662-3866-1","37662-3866-2","37662-3866-3","37662-3866-4","37662-3868-1","37662-3868-2","37662-3868-3","37662-3868-4","37662-3871-1","37662-3869-1","37662-3869-2","37662-3869-3","37662-3869-4","37662-3864-1","37662-3864-2","37662-3864-3"],"product_ndc":["37662-3864","37662-3867","37662-3870","37662-3865","37662-3866","37662-3868","37662-3871","37662-3869"],"generic_name":["GALLIUM OXYDATUM"],"product_type":["HUMAN OTC DRUG"],"substance_name":["GALLIUM OXIDE"],"manufacturer_name":["Hahnemann Laboratories, INC."],"is_original_packager":[true]},"purpose":[""],"version":"1","warnings":[""],"questions":[""],"ask_doctor":[""],"effective_time":"20230906","active_ingredient":["",""],"inactive_ingredient":[""],"instructions_for_use":[""],"indications_and_usage":[""],"dosage_and_administration":[""],"spl_product_data_elements":["Gallium Oxydatum Gallium Oxydatum GALLIUM OXIDE GALLIUM OXIDE SUCROSE Gallium Oxydatum Gallium Oxydatum SUCROSE GALLIUM OXIDE GALLIUM OXIDE Gallium Oxydatum Gallium Oxydatum GALLIUM OXIDE GALLIUM OXIDE SUCROSE Gallium Oxydatum Gallium Oxydatum GALLIUM OXIDE GALLIUM OXIDE SUCROSE Gallium Oxydatum Gallium Oxydatum GALLIUM OXIDE GALLIUM OXIDE SUCROSE Gallium Oxydatum Gallium Oxydatum SUCROSE GALLIUM OXIDE GALLIUM OXIDE Gallium Oxydatum Gallium Oxydatum SUCROSE GALLIUM OXIDE GALLIUM OXIDE Gallium Oxydatum Gallium Oxydatum GALLIUM OXIDE GALLIUM OXIDE SUCROSE"],"dosage_forms_and_strengths":[""],"pregnancy_or_breast_feeding":[""],"keep_out_of_reach_of_children":[""],"package_label_principal_display_panel":["Gallium Oxydatum 6C 5g Gallium Oxydatum 6C 30g Gallium Oxydatum 6C 100g Gallium Oxydatum 12C 5g Gallium Oxydatum 12C 30g Gallium Oxydatum 12C 100g Gallium Oxydatum 30C 1g Gallium Oxydatum 30C 5g Gallium Oxydatum 30C 30g Gallium Oxydatum 30C 100g Gallium Oxydatum 100C 1g Gallium Oxydatum 100C 5g Gallium Oxydatum 100C 30g Gallium Oxydatum 100C 100g Gallium Oxydatum 200C 1g Gallium Oxydatum 200C 5g Gallium Oxydatum 200C 30g Gallium Oxydatum 200C 100g Gallium Oxydatum 500C 1g Gallium Oxydatum 500C 5g Gallium Oxydatum 500C 30g Gallium Oxydatum 500C 100g Gallium Oxydatum 1M 1g Gallium Oxydatum 1M 5g Gallium Oxydatum 1M 30g Gallium Oxydatum 1M 100g Gallium Oxydatum LM1 30g"]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Powder","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Novartis","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[]},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GALLIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:05:35.265239+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Gallium","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T07:05:45.128851+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:05:43.611563+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GALLIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:05:44.060860+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:05:34.145934+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:05:34.145969+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201200/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:05:44.763055+00:00"}},"allNames":"gallium oxydatum","offLabel":[],"synonyms":["Gallium Oxydatum","GALLIUM OXIDE"],"timeline":[{"date":"20250328","type":"positive","source":"OpenFDA","milestone":"FDA approval (Novartis)"}],"approvals":[{"date":"20250328","orphan":false,"company":"NOVARTIS","regulator":"FDA"}],"brandName":"Gallium Oxydatum","ecosystem":[],"mechanism":{"target":"Glutamate carboxypeptidase 2, Prostate-specific antigen","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Gallium Oxydatum is a small molecule that binds to a specific protein or receptor, modulating its activity and leading to a therapeutic response."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Gallium","title":"Gallium","extract":"\nGallium is a chemical element; it has symbol Ga and atomic number 31. Discovered by the French chemist Paul-Émile Lecoq de Boisbaudran in Paris, France, 1875, \nelemental gallium is a soft, silvery metal at standard temperature and pressure. In its liquid state, it becomes silvery white. If enough force is applied, solid gallium may fracture conchoidally. Since its discovery in 1875, gallium has widely been used to make alloys with low melting points. It is also used in semiconductors, as a dopant in semiconductor substrates.","wiki_history":"==History==\nthumbnail|Small gallium droplets fusing together\nIn 1871, the existence of gallium was first predicted by Russian chemist Dmitri Mendeleev, who named it \"eka-aluminium\" from its position in his periodic table. He also predicted several properties of eka-aluminium that correspond closely to the real properties of gallium, such as its density, melting point, oxide character, and bonding in chloride.\n\n:{| class=\"wikitable\"\n|+ Comparison between Mendeleev's 1871 predictions and the known properties of gallium <!----> Later that year, Lecoq obtained the free metal by electrolysis of the hydroxide in potassium hydroxide solution.\n\nOriginally, de Boisbaudran determined the density of gallium as 4.7&nbsp;g/cm<sup>3</sup>, the only property that failed to match Mendeleev's predictions; Mendeleev then wrote to him and suggested that he should remeasure the density, and de Boisbaudran then obtained the correct value of 5.9&nbsp;g/cm<sup>3</sup>, that Mendeleev had predicted exactly. to reduce the melting point of alloys.\n\nFirst blue gallium nitride LED were developed in 1971–1973, but they were feeble. Only in the early 1990s Shuji Nakamura managed to combine GaN with indium gallium nitride and develop the modern blue LED, now making the basis of ubiquitous white LEDs, which Nichia commercialized in 1993. He and two other Japanese scientists received a Nobel in Physics in 2014 for this work.\n\nGlobal gallium production slowly grew from several tens of t/year in the 1970s til ca. 2010, when it passed 100 t/yr and rapidly accelerated, by 2024 reaching about 450 t/yr."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20250328, NOVARTIS)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"GALLIUM\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"GALLIUM\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=gallium","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=gallium","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/Gallium","fields":["history","overview"],"source":"Wikipedia"},{"id":6,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:23:42.668969","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:05:46.354961+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"gallium","indications":{"approved":[{"name":"Positron emission tomography","diseaseId":"positron-emission-tomography","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":["ACTH","Cushing's Syndrome"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":["Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-11-02"},{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":["Prostate Cancer"],"enrollment":26,"completionDate":"2026-11"},{"nctId":"NCT00001160","phase":"","title":"Studies on Tumors of the Thyroid","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1977-06-01","conditions":["Hurthle Cell Thyroid Cancer","Tall Cell Variant Thyroid Cancer","Follicular Thyroid Cancer","Thyroid Cancer","Papillary Thyroid Cancer"],"enrollment":2500,"completionDate":""},{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":["Prostatic Neoplasms"],"enrollment":469,"completionDate":"2026-09-30"},{"nctId":"NCT05939414","phase":"PHASE3","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-12","conditions":["Oligometastatic Prostate Cancer (OMPC)"],"enrollment":450,"completionDate":"2031-10-03"},{"nctId":"NCT04927416","phase":"PHASE2","title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-10-25","conditions":["Metastic Thyroid Cancer"],"enrollment":54,"completionDate":"2030-11-30"},{"nctId":"NCT06074120","phase":"NA","title":"Low-level Laser Therapy in Genitourinary Symptoms of Menopause","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2024-01-12","conditions":["Menopause Related Conditions"],"enrollment":27,"completionDate":"2026-02-26"},{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":["Prostate Cancer"],"enrollment":87,"completionDate":"2026-06-25"},{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":["Prostate Adenocarcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT06745804","phase":"PHASE1","title":"Study of 68Ga-R10602","status":"RECRUITING","sponsor":"Radionetics Oncology","startDate":"2024-12-10","conditions":["Locoregionally Recurrent Hormone-receptor Positive Breast Cancer","Metastatic Hormone Receptor Positive Breast Cancer","Hormone Receptor Positive Breast Adenocarcinoma"],"enrollment":36,"completionDate":"2026-07"},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":40,"completionDate":"2028-01-27"},{"nctId":"NCT07456709","phase":"NA","title":"Efficacy of Different Regiments of 980 nm Low-Level Laser Therapy to Reduce Pain Caused by Orthodontic Separators: A Randomized, Double-Blind, Split-Mouth Placebo-Controlled Study","status":"COMPLETED","sponsor":"Szeged University","startDate":"2021-11-26","conditions":["Orthodontic Pain (D013850)"],"enrollment":31,"completionDate":"2022-03-31"},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":["Prostatic Neoplasms"],"enrollment":1145,"completionDate":"2027-02-11"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT06427798","phase":"PHASE1,PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":["Somatostatin Receptor Positive","Gastrointestinal Neuroendocrine Tumors","Pheochromocytoma","Paragangliomas"],"enrollment":66,"completionDate":"2039-07-01"},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":["Prostate Carcinoma"],"enrollment":30,"completionDate":"2037-01-28"},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":["Prostate Carcinoma","Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8"],"enrollment":90,"completionDate":"2028-12-31"},{"nctId":"NCT07121244","phase":"PHASE1","title":"A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer","status":"RECRUITING","sponsor":"Radionetics Oncology","startDate":"2025-10-01","conditions":["Locoregionally Recurrent Hormone-receptor Positive Breast Cancer","Metastatic Hormone Receptor Positive Breast Cancer"],"enrollment":62,"completionDate":"2033-06-01"},{"nctId":"NCT06004661","phase":"PHASE2","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-04","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":20,"completionDate":"2026-06-17"},{"nctId":"NCT06404034","phase":"","title":"Expanded Access to Gallium Maltolate (GaM)","status":"NO_LONGER_AVAILABLE","sponsor":"Imaging Biometrics, LLC","startDate":"","conditions":["Glioblastoma","Refractory Glioblastoma","Glioblastoma Multiforme"],"enrollment":0,"completionDate":""},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":["Prostatic Neoplasm"],"enrollment":49,"completionDate":"2026-12-23"},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":["Digestive System Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":15,"completionDate":"2027-09-30"},{"nctId":"NCT04298541","phase":"PHASE2","title":"Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-06","conditions":["Meningioma"],"enrollment":6,"completionDate":"2027-06"},{"nctId":"NCT04074135","phase":"PHASE2","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-02","conditions":["VHL Pancreatic Neuroendocrine Tumors","Von Hippel-Lindau Disease","Neuroendocrine Tumors"],"enrollment":740,"completionDate":"2036-07-01"},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":["Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":130,"completionDate":"2033-01-01"},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":62,"completionDate":"2026-06-30"},{"nctId":"NCT05160597","phase":"EARLY_PHASE1","title":"Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-01-13","conditions":["Prostate Carcinoma"],"enrollment":30,"completionDate":"2027-01-07"},{"nctId":"NCT07400562","phase":"NA","title":"Electrophysiological Effects of Adjunct Low-Level Laser Therapy and Median Nerve Mobilization After Carpal Tunnel Release","status":"COMPLETED","sponsor":"Galala University","startDate":"2023-01-04","conditions":["Carpal Tunnel Syndrome (CTS)"],"enrollment":45,"completionDate":"2025-09-18"},{"nctId":"NCT06939036","phase":"PHASE1,PHASE2","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","status":"TERMINATED","sponsor":"Ariceum Therapeutics GmbH","startDate":"2025-07-01","conditions":["Small Cell Lung Cancer Extensive Stage","Merkel Cell Carcinoma"],"enrollment":2,"completionDate":"2025-12-31"},{"nctId":"NCT04459273","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-27","conditions":["Bladder Carcinoma","Cervical Carcinoma","Cholangiocarcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Hepatocellular Carcinoma","Malignant Adrenal Gland Neoplasm","Malignant Brain Neoplasm","Malignant Pleural Neoplasm","Malignant Skin Neoplasm","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Malignant Thymus Neoplasm","Neuroendocrine Neoplasm","Thyroid Gland Carcinoma","Urothelial Carcinoma","Cancer of Unknown Primary Site"],"enrollment":26,"completionDate":"2027-07-01"},{"nctId":"NCT05176223","phase":"PHASE2","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-01-30","conditions":["Advanced Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Unresectable Hepatocellular Carcinoma"],"enrollment":29,"completionDate":"2025-12-31"},{"nctId":"NCT05446376","phase":"PHASE2","title":"Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2024-11-22","conditions":["Infective Endocarditis"],"enrollment":40,"completionDate":"2026-11"},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":["Soft Tissue Sarcoma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":15,"completionDate":"2027-12-30"},{"nctId":"NCT03872778","phase":"PHASE1,PHASE2","title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2019-05-24","conditions":["Neoplasms"],"enrollment":35,"completionDate":"2025-11-27"},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":69,"completionDate":"2027-12-31"},{"nctId":"NCT06444412","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-12","conditions":["WHO Grade 3 Glioma","WHO Grade 4 Glioma"],"enrollment":25,"completionDate":"2028-07-31"},{"nctId":"NCT07331064","phase":"PHASE1","title":"Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Sarah Rumler","startDate":"2026-05-15","conditions":["High Grade Gliomas","Atypical Teratoid Rhabdoid Tumors (ATRT)","Diffuse Midline Glioma","DIPG","Diffuse Intrinsic Pontine Gliomas (DIPG)"],"enrollment":15,"completionDate":"2031-05-15"},{"nctId":"NCT04777071","phase":"PHASE2","title":"An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-05-17","conditions":["Biochemically Recurrent Prostate Carcinoma","Metastatic Castration-Resistant Prostate Carcinoma","Prostate Adenocarcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":141,"completionDate":"2030-07-15"},{"nctId":"NCT04040088","phase":"EARLY_PHASE1","title":"An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-23","conditions":["Ganglioneuroblastoma","Ganglioneuroma","Neuroblastoma"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT05562791","phase":"PHASE1","title":"A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-28","conditions":["Bladder Cancer"],"enrollment":20,"completionDate":"2026-09"},{"nctId":"NCT07176039","phase":"NA","title":"Comparison Between High-Intensity Laser Therapy and Extracorporeal Shockwave Therapy in the Treatment of Myofascial Pain Syndrome","status":"COMPLETED","sponsor":"MTI University","startDate":"2025-10-10","conditions":["Myofascial Pain Syndrome - Neck"],"enrollment":32,"completionDate":"2025-12-01"},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":106,"completionDate":"2028-11-24"},{"nctId":"NCT06881823","phase":"PHASE1,PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2033-06-01"},{"nctId":"NCT07301827","phase":"NA","title":"Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":["Renal Cell Carcinoma"],"enrollment":66,"completionDate":"2026-05-31"},{"nctId":"NCT07150806","phase":"PHASE1,PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":["Recurrent Meningioma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT05983198","phase":"PHASE1,PHASE2","title":"Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-07","conditions":["Prostate Cancer"],"enrollment":29,"completionDate":"2029-11-05"},{"nctId":"NCT06659705","phase":"PHASE2","title":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2025-12-02","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"enrollment":35,"completionDate":"2030-08-08"},{"nctId":"NCT07290049","phase":"NA","title":"Postoperative Pain After Pulpotomy in Children Using Calcium Silicate Cements With and Without Laser Therapy","status":"RECRUITING","sponsor":"University of Fujairah","startDate":"2025-04-24","conditions":["Symptomatic Irreversible Pulpitis","Symptomatic Irreversible Pulpitis (SIP)"],"enrollment":46,"completionDate":"2026-01-25"},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":["Oligometastatic Prostate Adenocarcinoma","Recurrent Prostate Adenocarcinoma"],"enrollment":107,"completionDate":"2031-10-31"},{"nctId":"NCT07284589","phase":"PHASE2","title":"Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","status":"RECRUITING","sponsor":"Akiva Mintz","startDate":"2025-12-11","conditions":["Healthy (Controls)","Healthy Volunteers","Neuroendocrine (NE) Tumors"],"enrollment":200,"completionDate":"2030-04-30"},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":["Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma","Unresectable Meningioma"],"enrollment":41,"completionDate":"2031-01-06"},{"nctId":"NCT04176497","phase":"PHASE2","title":"PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-07-16","conditions":["Prostate Cancer"],"enrollment":8,"completionDate":"2024-10-25"},{"nctId":"NCT04069299","phase":"","title":"Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-25","conditions":["Neuroendocrine Carcinoma"],"enrollment":30,"completionDate":"2026-01"},{"nctId":"NCT07262697","phase":"NA","title":"Laser Therapy for Patients With Nonspecific Neck Pain","status":"COMPLETED","sponsor":"Prince Sattam Bin Abdulaziz University","startDate":"2023-03-01","conditions":["Neck Pain","Non Specific Neck Pain"],"enrollment":60,"completionDate":"2024-04-01"},{"nctId":"NCT06479811","phase":"PHASE1","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-19","conditions":["Head and Neck Tumors","Kidney Cancers","Small Cell Lung Cancers","Pheochromocytoma/Paragangliomas","Gastrointestinal Neuroendocrine Tumors","Somatostatin Receptor Positive"],"enrollment":120,"completionDate":"2032-01-01"},{"nctId":"NCT04081701","phase":"PHASE4","title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-09-04","conditions":["CNS Tumors","Meningioma","Esthesioneuroblastoma","Hemangioblastoma","Medulloblastoma","Paraganglioma","Pituitary Adenoma"],"enrollment":200,"completionDate":"2038-12-31"},{"nctId":"NCT06247995","phase":"PHASE1,PHASE2","title":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-14","conditions":["Breast Cancer"],"enrollment":58,"completionDate":"2031-09-09"},{"nctId":"NCT04319276","phase":"PHASE1","title":"Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-11-11","conditions":["Glioblastoma"],"enrollment":26,"completionDate":"2027-03-01"},{"nctId":"NCT04762888","phase":"PHASE2","title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-02-24","conditions":["Hepatocellular Carcinoma"],"enrollment":52,"completionDate":"2025-06-26"},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma"],"enrollment":10,"completionDate":"2026-12-20"},{"nctId":"NCT06389786","phase":"NA","title":"Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-11","conditions":["Localized Prostate Carcinoma","Oligometastatic Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":50,"completionDate":"2026-05"},{"nctId":"NCT04712721","phase":"EARLY_PHASE1","title":"Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-14","conditions":["Glioblastoma Multiforme","Brain Neoplasms","Gastroesophageal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma"],"enrollment":14,"completionDate":"2024-07-01"},{"nctId":"NCT07213752","phase":"NA","title":"Diode Laser-Assisted Periodontal Therapy Enhances Clinical Outcomes for Deep Periodontal Pockets in Smokers","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2023-12-10","conditions":["Periodontitis","Periodontitis Stage III","Periodontal Disease","Diode Laser Therapy","Smoking","Malondialdehyde"],"enrollment":33,"completionDate":"2025-06-05"},{"nctId":"NCT05959629","phase":"NA","title":"Erbium, Chromium: Yttrium, Scandium, Gallium, Garnet (Er,Cr:YSGG) Laser in Root Canal Disinfection","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2023-10-11","conditions":["Endodontic Disease","Root Canal Infection"],"enrollment":56,"completionDate":"2024-05-02"},{"nctId":"NCT04631601","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-01-15","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":65,"completionDate":"2023-10-23"},{"nctId":"NCT07209878","phase":"PHASE2,PHASE3","title":"68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2020-01-10","conditions":["Prostate Cancer (Adenocarcinoma)"],"enrollment":100,"completionDate":"2026-06-30"},{"nctId":"NCT05518903","phase":"PHASE2","title":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-11-15","conditions":["Localized Pancreatic Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma","Stage 0 Pancreatic Cancer AJCC v8","Stage I Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8"],"enrollment":130,"completionDate":"2028-06-30"},{"nctId":"NCT07203222","phase":"NA","title":"Comparison of Effectiveness of Low Dose Laser and Transcutaneous Electrical Stimulation in Hemiplegic Shoulder","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2025-09-24","conditions":["Hemiplegic Shoulder Pain"],"enrollment":45,"completionDate":"2026-07-31"},{"nctId":"NCT04294043","phase":"PHASE1","title":"IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)","status":"RECRUITING","sponsor":"Chris Goss","startDate":"2021-06-17","conditions":["Nontuberculous Mycobacterium Infection"],"enrollment":40,"completionDate":"2027-03-31"},{"nctId":"NCT07132645","phase":"EARLY_PHASE1","title":"An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-09-16","conditions":["Neuroendocrine Tumor"],"enrollment":30,"completionDate":"2027-09-01"},{"nctId":"NCT05324332","phase":"NA","title":"68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-15","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT07161622","phase":"NA","title":"Comparing Low-Level Laser and Muscle Energy Techniques in Diabetic Frozen Shoulder","status":"NOT_YET_RECRUITING","sponsor":"University of Lahore","startDate":"2025-10","conditions":["Frozen Shoulder"],"enrollment":36,"completionDate":"2026-02"},{"nctId":"NCT03042468","phase":"PHASE1,PHASE2","title":"Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT06521775","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-08-12","conditions":["Metastatic Adenoid Cystic Carcinoma"],"enrollment":6,"completionDate":"2025-08-12"},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":236,"completionDate":"2029-12-31"},{"nctId":"NCT07052214","phase":"PHASE3","title":"PSMA PET Combined With MRI for the Detection of PCa","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-08-18","conditions":["PCA","Prostate Cancer","Prostatic Neoplasm","PSMA PET","Diagnostic Imaging","Elevated PSA","Positron Emission Tomography","Prostate Biopsy","Carcinoma of the Prostate"],"enrollment":204,"completionDate":"2026-11"},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2027-09"},{"nctId":"NCT04951817","phase":"NA","title":"68Ga-PSMA PET/CT for Ra223 Assessment","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-02","conditions":["Metastatic Prostate Cancer"],"enrollment":52,"completionDate":"2025-08-31"},{"nctId":"NCT04576871","phase":"EARLY_PHASE1","title":"Re-treatment 225Ac-J591 for mCRPC","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-29","conditions":["Prostate Cancer"],"enrollment":6,"completionDate":"2024-05-31"},{"nctId":"NCT05870579","phase":"PHASE1","title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-13","conditions":["Breast Cancer"],"enrollment":48,"completionDate":"2032-01-26"},{"nctId":"NCT07128134","phase":"NA","title":"Evaluation of the Effects of the Low-level Laser Therapy as an Adjunct to Nonsurgical Treatment in Patients With Periimplantitis","status":"NOT_YET_RECRUITING","sponsor":"Mustafa Kemal University","startDate":"2025-08-20","conditions":["Periimplantitis"],"enrollment":72,"completionDate":"2026-06-30"},{"nctId":"NCT05956093","phase":"NA","title":"68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09-25","conditions":["High Grade Serous Ovarian Cancer (HGSOC)"],"enrollment":30,"completionDate":"2026-05-30"},{"nctId":"NCT06359717","phase":"","title":"Prospective Validation of PSMA-RADS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2023-01-01","conditions":["Cancer Prostate"],"enrollment":477,"completionDate":"2025-08-20"},{"nctId":"NCT06270394","phase":"NA","title":"FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Anhui Medical University","startDate":"2022-04-28","conditions":["Malignant Tumors","Positron-Emission Tomography"],"enrollment":22,"completionDate":"2025-05-31"},{"nctId":"NCT07119242","phase":"PHASE3","title":"Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2024-01-08","conditions":["NETs"],"enrollment":95,"completionDate":"2025-12-31"},{"nctId":"NCT07117760","phase":"PHASE1,PHASE2","title":"Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-04-22","conditions":["Prostate Cancer"],"enrollment":20,"completionDate":"2029-12-31"},{"nctId":"NCT07117214","phase":"PHASE1","title":"A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-08-20","conditions":["Breast Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":36,"completionDate":"2027-01-26"},{"nctId":"NCT04147494","phase":"EARLY_PHASE1","title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-11-05","conditions":["Breast Carcinoma","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Head and Neck Carcinoma","Kidney Carcinoma","Lung Carcinoma","Ovarian Carcinoma","Pancreatic Carcinoma","Solid Neoplasm","Uterine Corpus Cancer"],"enrollment":29,"completionDate":"2031-10-17"},{"nctId":"NCT07118176","phase":"PHASE1","title":"Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-08-01","conditions":["Anal Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Cholangiocarcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Lung Carcinoma","Malignant Adrenal Gland Neoplasm","Malignant Brain Neoplasm","Malignant Neoplasm of Unknown Primary","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Malignant Uterine Neoplasm","Neuroendocrine Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Penile Carcinoma","Pleural Carcinomatosis","Primary Peritoneal Carcinoma","Prostate Carcinoma","Salivary Gland Carcinoma","Sarcoma","Skin Carcinoma","Solitary Fibrous Tumor","Thymus Carcinoma","Thyroid Gland Carcinoma","Thyroid Gland Medullary Carcinoma","Urothelial Carcinoma","Vaginal Carcinoma"],"enrollment":30,"completionDate":"2027-09-07"},{"nctId":"NCT04457258","phase":"EARLY_PHASE1","title":"68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-09-08","conditions":["Metastatic Sarcoma","Recurrent Sarcoma","Sarcoma"],"enrollment":18,"completionDate":"2027-07-21"},{"nctId":"NCT01879657","phase":"NA","title":"68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"Radio Isotope Therapy of America","startDate":"2013-03-01","conditions":["Neuroendocrine Carcinoma"],"enrollment":169,"completionDate":"2017-12-05"},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":163,"completionDate":"2023-12-31"},{"nctId":"NCT06580015","phase":"NA","title":"[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-03-25","conditions":["Prostate Carcinoma"],"enrollment":20,"completionDate":"2027-01-09"},{"nctId":"NCT03448458","phase":"PHASE2","title":"Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-22","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7"],"enrollment":17,"completionDate":"2023-02-06"},{"nctId":"NCT06067269","phase":"PHASE2","title":"Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-03-28","conditions":["Prostate Adenocarcinoma","Stage II Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8"],"enrollment":95,"completionDate":"2027-12-01"},{"nctId":"NCT04457232","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-09-09","conditions":["Metastatic Malignant Neoplasm in the Prostate Gland","Prostate Carcinoma","Recurrent Prostate Carcinoma"],"enrollment":30,"completionDate":"2026-05-30"},{"nctId":"NCT03335670","phase":"EARLY_PHASE1","title":"Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yusuf Menda","startDate":"2017-11-03","conditions":["Neuroendocrine Tumors"],"enrollment":30,"completionDate":"2030-06-30"},{"nctId":"NCT07043868","phase":"NA","title":"Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers","status":"NOT_YET_RECRUITING","sponsor":"Federal University of Piaui","startDate":"2026-01-10","conditions":["Diabete Type 2","Diabetic Foot Ulcer","Photobiomodulation","Low Level Laser Therapy"],"enrollment":136,"completionDate":"2028-01-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Powder","formulations":[{"form":"POWDER","route":"ORAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"46F059V66A","SPL_ID":"04ba7ec2-1ea0-b828-e063-6394a90abb12","chemblId":"CHEMBL1201200"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Novartis","relationship":"Original Developer"}],"publicationCount":14738,"therapeuticAreas":["Urology"],"applicationNumber":"NDA215841","biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"2025","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"NOVARTIS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":18,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:05:46.354961+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}